Want to see ORIC full AI Analyst Report?
Top Page
Oric Pharmaceuticals
(NASDAQ:ORIC)
Select Model
Select Model
Rating:56Neutral
Price Target:
$12.00
▼(-0.83% Downside)
Action:Reiterated
Date:07/31/26
The score is primarily held back by weak financial performance—no revenue, widening losses, and significant negative free cash flow—despite a low-debt balance sheet. Technicals provide the main support, with the stock trading above key moving averages across multiple timeframes. Valuation is difficult to assess due to negative earnings and no dividend yield, while recent corporate events modestly improve governance/recruiting flexibility but do not offset ongoing cash-burn risk.
Positive Factors
Low leverage / strong balance sheet
ORIC’s near-zero debt and sizable equity provide durable financial flexibility for a clinical-stage biotech. Low leverage reduces bankruptcy risk and allows management to fund R&D spending and milestone-driven trials without immediate solvency pressure, supporting multi-quarter program execution.
Negative Factors
No revenue; widening net losses
ORIC’s lack of product revenue and materially larger net losses reflect continued pre-revenue status and rising R&D spend. Over the medium term this increases dependence on financing and heightens execution risk: trial setbacks or slower enrollment directly extend time to self-sustaining revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
ORIC’s near-zero debt and sizable equity provide durable financial flexibility for a clinical-stage biotech. Low leverage reduces bankruptcy risk and allows management to fund R&D spending and milestone-driven trials without immediate solvency pressure, supporting multi-quarter program execution.
Read all positive factors
Oric Pharmaceuticals (ORIC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.20B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth23.91%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.44
Shares Outstanding103,517,560
10 Day Avg. Volume1,549,507
30 Day Avg. Volume1,650,377
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.67Price Target Upside62.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.47
Revenue Forecast (FY)N/A
Oric Pharmaceuticals Business Overview & Revenue Model
Company Description
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage dr...
How the Company Makes Money
ORIC does not have recurring revenue from the sale of approved pharmaceutical products; as a clinical-stage biotech, it typically finances operations primarily through capital raising (e.g., issuing equity and other financing activities). Informat...
Oric Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -320.00K | -1.22M | -1.11M | -1.03M | 0.00 | 0.00 |
| EBITDA | -134.03M | -128.25M | -126.74M | -99.67M | -85.80M | -77.82M |
| Net Income | -135.21M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
Balance Sheet | ||||||
| Total Assets | 436.76M | 411.00M | 274.14M | 254.69M | 250.36M | 298.64M |
| Cash, Cash Equivalents and Short-Term Investments | 281.93M | 281.49M | 255.96M | 208.19M | 206.27M | 236.98M |
| Total Debt | 3.30M | 11.55M | 3.18M | 10.21M | 12.10M | 1.93M |
| Total Liabilities | 21.20M | 26.64M | 31.02M | 30.60M | 28.01M | 25.67M |
| Stockholders Equity | 415.56M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
Cash Flow | ||||||
| Free Cash Flow | -111.36M | -114.08M | -113.85M | -86.54M | -77.22M | -60.48M |
| Operating Cash Flow | -110.88M | -113.37M | -112.66M | -85.69M | -75.14M | -59.54M |
| Investing Cash Flow | -188.46M | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Financing Cash Flow | 306.39M | 245.26M | 126.55M | 85.66M | 25.23M | 49.13M |
Oric Pharmaceuticals Technical Analysis
Positive
12.10
Price Trends
9.60
Positive
9.96
Positive
10.59
Positive
Market Momentum
0.50
Negative
69.87
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 12.1 is above the 20-day moving average (MA) of 11.08, above the 50-day MA of 9.60, and above the 200-day MA of 10.59, indicating a bullish trend. The MACD of 0.50 indicates Negative momentum. The RSI at 69.87 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.
Oric Pharmaceuticals Risk Analysis
Oric Pharmaceuticals disclosed 98 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oric Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $2.61B | -56.64 | -24.53% | ― | ― | 27.89% | |
62 Neutral | $8.81B | -45.11 | -31.25% | ― | ― | 22.31% | |
60 Neutral | $8.58B | -22.99 | -43.02% | ― | -100.00% | -24.90% | |
56 Neutral | $1.20B | -7.69 | -35.33% | ― | ― | 23.91% | |
55 Neutral | $715.13M | 68.87 | 4.75% | ― | 15.66% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $545.46M | -2.30 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
ORIC
Oric Pharmaceuticals
11.07
0.95
9.39%
SYRE
Spyre Therapeutics
98.33
82.07
504.74%
TRVI
Trevi Therapeutics
18.25
10.92
148.98%
PRAX
Praxis Precision Medicines
307.83
253.74
469.11%
PHAR
Pharming Group
10.08
-0.88
-8.03%
PRME
Prime Medicine, Inc.
2.92
-1.12
-27.72%
Oric Pharmaceuticals Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan
Positive
Jul 30, 2026
On July 28, 2026, ORIC Pharmaceuticals’ board approved an amended and restated 2022 Inducement Equity Incentive Plan, increasing the shares of common stock reserved for issuance to an aggregate of 3,350,000. The plan, adopted without stockho...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Oric Shareholders Approve Equity Plan, Governance Measures
Positive
Jun 22, 2026
On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an amended and restated 2020 Equity Incentive Plan that adjusts its evergreen feature, caps incentive stock option issuances at 10 million shares within the plan’s reserve, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.